Presentation is loading. Please wait.

Presentation is loading. Please wait.

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Similar presentations


Presentation on theme: "Long-term study of mycophenolate mofetil treatment in IgA nephropathy"— Presentation transcript:

1 Long-term study of mycophenolate mofetil treatment in IgA nephropathy
Sydney C.W. Tang, Anthony W.C. Tang, Sunny S.H. Wong, Joseph C.K. Leung, Yiu Wing Ho, Kar Neng Lai  Kidney International  Volume 77, Issue 6, Pages (March 2010) DOI: /ki Copyright © 2010 International Society of Nephrology Terms and Conditions

2 Figure 1 Kaplan–Meier analysis of overall renal survival of 40 IgAN subjects over the 6-year follow-up period. Ctl, control; MMF, mycophenolate mofetil. Kidney International  , DOI: ( /ki ) Copyright © 2010 International Society of Nephrology Terms and Conditions

3 Figure 2 Kaplan–Meier analysis of the likelihood of not reaching the primary composite end point of doubling of serum creatinine, dialysis, or death of 40 IgAN subjects over the 6-year follow-up period. Kidney International  , DOI: ( /ki ) Copyright © 2010 International Society of Nephrology Terms and Conditions

4 Figure 3 Proteinuria change from baseline to study end. (a) Changes in urinary protein excretion during follow-up. The geometric mean values, with 95% confidence intervals, are shown. *P=0.019, †P=0.023, ‡P=0.007 versus the control group at the corresponding time point. (b) Changes in urinary albumin-to-creatinine ratio during follow-up. The geometric mean values, with 95% confidence intervals, are shown. *P=0.019, †P=0.006, ‡P=0.027 versus the control group at the corresponding time point. Kidney International  , DOI: ( /ki ) Copyright © 2010 International Society of Nephrology Terms and Conditions

5 Figure 4 Annual change in estimated GFR. (a) The rates of change in eGFR over the study period were calculated for each patient by linear regression analysis. The median change in eGFR, indicted by the horizontal line, was  ml/min per 1.73 m2 per year in the MMF group and  ml/min per 1.73 m2 per year in the control group (P=0.021). (b) The annualized rates of change in eGFR over the study period according to the type of angiotensin blockade given: ACEi (open circle), ARB (half-filled circle), and combination (solid circle). Kidney International  , DOI: ( /ki ) Copyright © 2010 International Society of Nephrology Terms and Conditions

6 Figure 5 Changes in systolic and diastolic blood pressure. Between-group differences for both systolic and diastolic blood pressures were not statistically significant at each time point. Kidney International  , DOI: ( /ki ) Copyright © 2010 International Society of Nephrology Terms and Conditions

7 Figure 6 Pearson's correlation between reduction in urinary protein excretion at 6 months and the slope of eGFR over time. Kidney International  , DOI: ( /ki ) Copyright © 2010 International Society of Nephrology Terms and Conditions


Download ppt "Long-term study of mycophenolate mofetil treatment in IgA nephropathy"

Similar presentations


Ads by Google